Skip to main content

Proguanil Disease Interactions

There are 2 disease interactions with proguanil.

Major

Proguanil (applies to proguanil) severe renal impairment

Major Potential Hazard, Moderate plausibility. Applicable conditions: Renal Dysfunction

Atovaquone and Proguanil tablets are contraindicated for prophylaxis of P. falciparum malaria in patients with severe renal impairment (creatinine clearance <30 mL/min) because of pancytopenia in patients with severe renal impairment treated with proguanil. Use with caution for the treatment of malaria in patients with severe renal impairment, only if the benefits of the 3-day treatment regimen outweigh the potential risks associated with increased drug exposure. No dosage adjustments are needed in patients with mild (creatinine clearance 50 to 80 mL/min) or moderate (creatinine clearance 30 to 50 mL/min) renal impairment.

References

  1. (2001) "Product Information. Malarone (atovaquone-proguanil)." Glaxo Wellcome
Moderate

Proguanil (applies to proguanil) hepatic impairment

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Liver Disease

No proguanil dosage adjustments are needed in patients with mild or moderate hepatic impairment, however, no trials have been conducted in patients with severe hepatic impairment. Caution is advised, as elevated liver laboratory tests and cases of hepatitis and hepatic failure requiring liver transplantation have been reported with prophylactic use of atovaquone and proguanil hydrochloride tablets.

References

  1. (2001) "Product Information. Malarone (atovaquone-proguanil)." Glaxo Wellcome

Proguanil drug interactions

There are 35 drug interactions with proguanil.


Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.